The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
First Participant Dosed in Phase 1 Clinical Trial for RXC008
Potential first-in-class GI-targeted ROCK inhibitor for fibrostenotic Crohn's disease enters Phase 1 study
RXC008 is the second wholly-owned asset from Redx's ROCK portfolio to enter clinical development
Alderley Park, UK, 28 February 2024 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of fibrotic disease and cancer today announces that the first participant has been dosed in a Phase 1 clinical trial for RXC008. RXC008 is a wholly-owned gastro-intestinal (GI) targeted Rho Associated Coiled-Coil Containing Protein Kinase (ROCK) inhibitor, being developed as a potential first-in-class treatment for patients with fibrostenotic Crohn's disease. The primary objective of this first-in-human study is to evaluate the safety and pharmacokinetic (PK) profile of the drug and it is expected that results from the healthy volunteer cohorts will be available by the end of 2024.
Lisa Anson, Chief Executive Officer, Redx Pharma commented: "We are delighted to confirm that the first participant has been dosed in the RXC008 Phase 1 clinical study. RXC008 is a potential first-in-class treatment for patients with fibrostenotic Crohn's disease, a debilitating condition where successive surgeries are the only treatment option available today. This milestone represents the sixth asset from Redx to enter clinical development, continuing our strong track record in small molecule drug discovery as a result of our world-class medicinal chemistry and translational science expertise."
Redx to Present at the TD Cowen 44th Annual Health Care Conference
Alderley Park, UK, 26 February 2024 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of fibrotic disease and cancer today announces that Lisa Anson, Chief Executive Officer, and Peter Collum, Chief Financial Officer, will be presenting in-person at the TD Cowen 44th Annual Health Care Conference in Boston, MA, on Wednesday 6 March at 9:50am ET. Alongside the presentation, the Company will also be available for one-to-one meetings.
The presentation will be webcast live and can be accessed via the following link: https://wsw.com/webcast/cowen154/redx.l/2263774
Following the event, a recording will be made available on the investor section of the Company's website at: https://www.redxpharma.com/investor-centre/presentations-analyst-reports-documents-and-videos/
23 February 2024
Further to the announcements of 18 September 2023 and 2 January 2024, Corcel Plc (London AIM: CRCL) provides an update on its unsecured convertible loan note facility. The facility has the potential to extend £10,000,000 of funding to the Company, attracts a 12% interest rate per annum and is convertible into new ordinary shares over the three-year life of the notes at a fixed price of £0.008.
To date, £1,000,000 has been drawn down from the facility with £250,000 of this subsequently converted into equity as announced on 2 January 2024.
The Company is currently in discussions with the lender, Extraction Srl, around the quantum and timing of the next drawdown against the facility, and the Company will update the markets on these discussions in due course. The Company expects the proceeds of this drawdown to fund its ongoing activities in the Kwanza Basin, Angola.
Extraction Srl is 45% owned by the Executive Chairman of Corcel Plc, Antoine Karam.